Drug category with potential risk | Cases (n=1541) | Controls (n=5677) | OR | 95% CI | P value | ||
n | % | n | % | ||||
Antiplatelets | 44 | 2.9 | 150 | 2.6 | 1.01 | 0.69 to 1.46 | 0.977 |
Anticoagulants | 7 | 0.5 | 9 | 0.2 | 3.11 | 1.16 to 8.35 | 0.024 |
Statins | 60 | 3.9 | 294 | 5.2 | 0.68 | 0.50 to 0.92 | 0.012 |
Sodium channel blockers | 10 | 0.6 | 30 | 0.5 | 1.28 | 0.61 to 2.67 | 0.511 |
Class III antiarrhythmic drugs | 45 | 2.9 | 35 | 0.6 | 6.80 | 3.96 to 11.66 | <0.001 |
ACE inhibitor | 9 | 0.6 | 18 | 0.3 | 1.83 | 0.80 to 4.20 | 0.156 |
Thiazides | 11 | 0.7 | 67 | 1.2 | 0.59 | 0.31 to 1.14 | 0.116 |
NSAIDs | 302 | 19.6 | 566 | 10.0 | 2.43 | 2.04 to 2.88 | <0.001 |
Antiepileptics | 16 | 1.0 | 53 | 0.9 | 1.07 | 0.59 to 1.94 | 0.836 |
Sulfamethoxazole/trimethoprim | 14 | 0.9 | 17 | 0.3 | 2.89 | 1.36 to 6.13 | 0.006 |
Quinolones | 175 | 11.4 | 246 | 4.3 | 2.93 | 2.35 to 3.65 | <0.001 |
Tetracyclines | 40 | 2.6 | 69 | 1.2 | 2.30 | 1.50 to 3.52 | <0.001 |
Beta-lactams | 639 | 41.5 | 1940 | 34.2 | 1.62 | 1.39 to 1.89 | <0.001 |
Anti-TB drugs | 14 | 0.9 | 28 | 0.5 | 2.14 | 0.94 to 4.89 | 0.071 |
EGFR inhibitors | 73 | 4.7 | 22 | 0.4 | 16.48 | 9.57 to 28.39 | <0.001 |
Pyrimidine | 16 | 1.0 | 50 | 0.9 | 1.18 | 0.63 to 2.21 | 0.599 |
Anthracyclines | 9 | 0.6 | 12 | 0.2 | 3.09 | 1.24 to 7.70 | 0.015 |
EGFR, epidermal growth factor receptor; NSAIDs, non-steroidal anti-inflammatory drugs.